Mesoblast Limited On Track For Phase 3 Bone Marrow Transplant Trial Following Positive Meeting With United States FDA

Melbourne, Aug 16, 2010 (ABN Newswire) - Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today provided market guidance on its Phase 3 bone marrow transplant program following a formal meeting with the United States Food and Drug Administration (FDA).